On November 16, 2026, FDA issued a proposed rule that would permit N-acetyl-L-cysteine (NAC) to be lawfully marketed in or as a dietary supplement, provided the product otherwise complies with requirements applicable to dietary supplements. The proposal is FDA’s first use of its statutory authority to permit an ingredient approved as a drug to be lawfully marketed in dietary supplements, and its first detailed explanation of the showing FDA believes is necessary to obtain such an exception. If finalized, the rule would establish a regulation entitled “dietary ingredients not excluded from the dietary supplement definition,” with NAC as the first entry and a placeholder for future additions.
Section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act (FDCA) (“the drug exclusion provision”) excludes from the definition of “dietary supplement” certain articles that were approved or authorized for investigation as drugs, antibiotics, or biologics before being marketed as dietary supplements or foods unless FDA has, in its discretion, issued a regulation, after notice and comment, “finding that the article would be lawful” under the FDCA.
NAC was approved as a new drug in 1963, and because NAC was not marketed as a dietary supplement or food before that approval, FDA has taken the position that NAC is excluded from the dietary supplement definition. In 2021, FDA received two citizen petitions asking the Agency to conclude that NAC is not excluded from the dietary supplement definition, one of which requested that FDA initiate rulemaking to permit NAC’s use in dietary supplements. In 2022, FDA announced a temporary enforcement discretion policy for certain NAC products labeled as dietary supplements until the Agency either completed a rulemaking or denied the rulemaking request.
FDA identifies one threshold requirement and two substantive conditions governing when it may consider exercising its discretionary rulemaking authority.
First, the article must qualify as a “dietary ingredient” under section 201(ff)(1) of the FDCA. FDA concluded that NAC satisfies this threshold because it is a dietary substance for use by humans to supplement the diet by increasing total dietary intake.
FDA then interpreted the structure, purpose, and legislative history of the Dietary Supplement Health and Education Act of 1994 as limiting an exception to circumstances in which both of the following conditions are met: (1) regulation as a dietary supplement would provide adequate safeguards, including appropriate review and oversight; and (2) allowing the substance in or as a dietary supplement would be unlikely to impede new drug development. FDA presents these as constraints on its discretion and does not specify the precise evidence required in every case.
- Safety and regulatory safeguards. FDA evaluated whether the dietary supplement framework would provide adequate safeguards by conducting a supplement-specific safety assessment. FDA declined to rely on the safety findings supporting NAC’s drug approvals because drug review weighs risks against therapeutic benefits, whereas a dietary supplement safety assessment generally considers risk alone. FDA instead performed a systematic review of orally administered NAC, which identified 41 high-confidence studies at doses of up to 9,000 mg/day and durations of up to three years. Of these studies, only one found a significant adverse effect—non-serious nausea. Using the National Toxicology Program’s five-point scale, FDA assigned NAC a “minimal” level of concern. Because the studied doses encompassed the recommended servings of marketed NAC products, FDA concluded that this minimal concern translates to a “reasonable expectation of safety” for supplement use.
- Effect on drug development. FDA also considered whether lawful supplement use would undermine incentives for drug development. FDA noted that NAC products improperly labeled as dietary supplements have been sold since at least 1991, and that there is no evidence this has negatively impacted NAC drug development. FDA pointed to continuous drug approval since 1963, 19 current ANDAs (most approved after 1991), and 832 clinical trials. FDA also noted that it received no comments on its 2022 draft enforcement discretion guidance expressing concern that allowing NAC in supplements would impede drug development. FDA therefore found no reason to expect that legal supplement marketing would adversely affect current or future drug development, while specifically inviting comment on that conclusion.
FDA’s discussion offers a potential roadmap for requests regarding other ingredients subject to the drug exclusion provision. A persuasive request would likely need to establish: (1) that the article qualifies as a dietary ingredient; (2) a robust, use-specific safety record supporting a reasonable expectation of safety at proposed supplement doses and under proposed conditions of use; and (3) evidence that supplement marketing is unlikely to impair drug-development incentives. Relevant evidence may include:
- Systematic safety reviews
- Exposure and dosage comparisons
- History and scale of supplement marketing
- Continued drug approvals and clinical research despite that marketing
- Input from drug sponsors or other stakeholders
NAC’s decades of supplement sales, substantial clinical literature, continued drug development, and absence of identified sponsor objections made it a comparatively strong candidate. Ingredients lacking a similarly developed record may face a more difficult path.
The proposed regulation addresses FDCA sections 201(ff)(3)(B) and 301(ll). Dietary supplements are deemed foods under section 201(ff) and section 301(ll) generally prohibits introducing food to which an approved drug has been added unless an exception applies. FDA explains that a rule under section 201(ff)(3)(B) alone would therefore produce an “illogical result” because NAC would become eligible for use in a dietary supplement, but adding it to that supplement would remain a prohibited act under 301(ll). Proposed § 190.1 addresses both provisions in a single regulation by providing that NAC is not excluded from the dietary supplement definition and that adding NAC to a dietary supplement is not prohibited under section 301(ll).
- Application to Dietary Supplements, Not Conventional Foods. The proposed exception is limited to NAC used “in or as a dietary supplement,” and language on section 301(ll) applies only to the addition of NAC “to a dietary supplement.” The proposal therefore would not authorize adding NAC to a conventional food.
- NDI notifications. FDA expressly concludes that NAC is not a new dietary ingredient (NDI) because evidence shows it was marketed in the U.S. as a dietary supplement before October 15, 1994. Accordingly, an NDI notification is not required prior to marketing NAC as or in a dietary supplement after the rule is finalized. However, that conclusion is specific to NAC; other ingredients FDA may consider for future rulemaking under the proposed regulation may require an NDI notification.
FDA proposes that, if finalized, the rule will take effect immediately upon publication. At that time, FDA intends to withdraw its 2022 NAC enforcement-discretion guidance.
Comments are due January 16, 2027 in Docket No. FDA-2025-N-2699. For parties considering future requests under section 201(ff)(3)(B), the comment period provides an opportunity to address how FDA should apply its new framework.
If you have any questions concerning the material discussed in this client alert, please contact the members of our Food, Beverage, and Dietary Supplements practice.